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Abstract
Purpose Valproic acid (VPA) is suggested to be therapeutically beneficial in combination with interferon-alpha (IFNα) in 
various cancers. Therefore, we examined IFNα and VPA alone and in combinations in selected AML models, examining 
immune regulators and intracellular signaling mechanisms involved in phospho-proteomics.
Methods The anti-leukemic effects of IFNα and VPA were examined in vitro and in vivo. We mapped the in vitro phospho-
protein modulation by IFNα-2b and human IFNα-Le in MOLM-13 cells by IMAC/2D DIGE/MS analysis and phospho-flow 
cytometry, and in primary healthy and AML patient-derived PBMCs by CyTOF. In vivo, IFNα-Le and VPA efficacy were 
investigated in the immunodeficient NOD/Scid IL2γ−/− MOLM-13Luc+ mouse model and the syngeneic immunocompetent 
BNML rat model.
Results IFNα-2b and IFNα-Le differed in the modulation of phospho-proteins involved in protein folding, cell stress, cell 
death and p-STAT6 Y641, whereas VPA and IFNα-Le shared signaling pathways involving phosphorylation of Akt (T308), 
ERK1/2 (T202/T204), p38 (T180/Y182), and p53 (S15). Both IFNα compounds induced apoptosis synergistically with 
VPA in vitro. However, in vivo, VPA monotherapy increased survival, but no benefit was observed by IFNα-Le treatment. 
CyTOF analysis of primary human PBMCs indicated that lack of immune-cell activation could be a reason for the absence 
of response to IFNα in the animal models investigated.
Conclusions IFNα-2b and IFNα-Le showed potent and synergistic anti-leukemic effects with VPA in vitro but not in leukemic 
mouse and rat models in vivo. The absence of IFNα immune activation in lymphocyte subsets may potentially explain the 
limited in vivo anti-leukemic effect of IFNα-monotherapy in AML.
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pDC  Plasmacytoid dendritic cell
DN T cell  Double negative T cell
NK  Natural killer
MFI  Mean fluorescence intensity
UPR  Unfolded protein response
ITD  Internal tandem duplication
Background
Acute myeloid leukemia (AML) is a heterogeneous aggres-
sive blood cancer characterized by a block in differentia-
tion, elevated threshold for undergoing apoptosis and exces-
sive proliferation of myeloid progenitor cells (Dohner et al. 
2017). Median age of diagnosis is approximately 70 years 
(Juliusson et al. 2009), and 5 year overall survival is only 5% 
for patients older than 65 years (Visser et al. 2012), under-
scoring the need of more effective therapy with acceptable 
toxicity. IFNα has been tested in AML as induction ther-
apy (Berneman et al. 2010), as a post-remission strategy 
to prevent recurrence after chemotherapy (Goldstone et al. 
2001), in consolidation with allogeneic hematopoietic stem 
cell transplantation (HSCT) (Klingemann et al. 1991), and 
as a salvage therapy for patients relapsing upon allogeneic 
HSCT (Arellano et al. 2007). Case reports showing complete 
remission after IFNα monotherapy in secondary AML fol-
lowing essential thrombocytosis and/or myelofibrosis may 
indicate that subsets of patients are particularly sensitive to 
IFNα (Berneman et al. 2010; Dagorne et al. 2013). IFNα 
also seems to be effective to prevent relapse in minimal 
residual disease (MRD) positive patients after HSCT (Mo 
et al. 2015), while no effect has been reported in children’s 
relapsed/refractory leukemia (Ochs et al. 1986).
Several formulations of therapeutic IFNα have been 
available for clinical use. In addition to the most used 
recombinant IFNα-2b, a human purified preparation of 
IFNα consisting of six different subtypes (IFNα-Le) has 
been shown beneficial in melanoma (Stadler et al. 2006). 
IFNα-Le consists of IFNα1, -α2, -α8, -α10, -α14 and -α21, 
whereof IFNα2 and IFNα14 are glycosylated. Intriguingly, 
the IFNα-induced molecular phospho-signaling response has 
not systematically been characterized in cancer cells, and the 
anti-leukemic effect of IFNα-Le has previously never been 
compared with recombinant IFNα-2b.
The combination of IFNα with the histone deacetylase 
inhibitor valproic acid (VPA) has been reported to be syn-
ergistic in several solid cancer models (Jones et al. 2009; 
Iwahashi et al. 2011; Hudak et al. 2012), suggesting that 
this combination could represent a valuable novel therapeu-
tic strategy in AML. VPA is an anticonvulsant also used 
in bipolar disease with well-characterized side effects. Its 
anti-leukemic effect has been examined in combination with 
all-trans retinoic acid (ATRA) (Trus et al. 2005), 5-azacy-
tidine or low dose cytarabine with responses in up to 20% 
of the AML patients (Kuendgen et al. 2006; Raffoux et al. 
2010; Corsetti et al. 2011; Fredly et al. 2013).
In this study, we compared recombinant and purified 
human IFNα formulations and found specific regulation of 
signaling pathways. The combination of IFNα with VPA 
was synergistic in vitro, but even though in vivo experiments 
supported the anti-leukemic effect of VPA, we did not find 




MOLM-13 (DSMZ, Braunschweig, Germany) and IPC-81 
cells [obtained from Dr. Michel Lanotte (Lacaze et al. 1983)] 
were incubated with; 250 or 2000 IU/mL IFNα-2b (Intron 
A, Schering-Plough, Kenilworth, New Jersey, USA), 250 
or 2000 IU/mL IFNα-Le (Multiferon, generously provided 
by Sobi Swedish Orphan Biovitrum, Stockholm, Sweden), 
1 mM VPA (Desitin Pharma AS, Hamburg, Germany) or a 
combination of 2000 IU/mL IFNα-2b or IFNα-Le and 1 mM 
VPA for 15 min or 48 h. AML patient peripheral blood 
mononuclear cells (PBMCs, n = 12; six normal karyotype, 
six complex karyotype, Table 1) and healthy donor PBMCs 
(n = 5) were collected after written informed consent in com-
pliance with the Declaration of Helsinki (REK2016/253, 
REK2012/2247). PBMCs were isolated by Ficoll separation 
(Sigma-Aldrich, Darmstadt, Germany) and cryopreserved 
in liquid nitrogen for long-term storage. The cells were 
thawed, centrifuged for 5 min at 300g before incubation for 
15 min in StemSpan (STEMCELL Technologies, Inc. Van-
couver, Canada) added 9% DMEM (Sigma-Aldrich) and 1% 
DNase I Solution (STEMCELL Technologies). Cells were 
then plated at  1x106 cells/mL and added media, 2000 IU/
mL IFNα-2b, 1 mM VPA or a combination of IFNα-2b and 
VPA for 48 h before counting, washing with Maxpar PBS 
(Fluidigm, San Francisco, CA, USA), fixed with 2% para-
formaldehyde (PFA) in Maxpar PBS for 10 min at 37 °C, 
followed by freezing at − 80 °C for storage prior to analysis.
Staining of primary cells for mass cytometry (CyTOF)
To assure comparability across samples from different 
donors, the samples were barcoded using a commercially 
available metal barcoding kit (Fluidigm), according to the 
manufacturer’s instructions. Twenty samples were multi-
plexed, making a total of four pooled samples, each con-
taining AML patient and healthy donor samples.
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Fig. 1  Phospho-signaling 
induced by recombinant 
IFNα-2b and human IFNα-Le 
in human AML MOLM-13 
cells. a MOLM-13 cells were 
treated with 200 or 2000 IU/
mL IFNα-2b or IFNα-Le for 
48 h. Forty-seven proteins 
were significantly differen-
tially regulated by IFNα and 
are encircled and identified by 
protein name. The highlighted 
protein MRPS23 is visual-
ized by the three-dimensional 
visualization of cyanine-labeled 
protein emission intensities 
indicating the abundance of 
MRPS23. MOLM-13 cells 
were further analyzed by flow 
cytometry after treatment with 
b 250 IU/mL or c 2000 IU/mL 
IFNα-2b or IFNα-Le (n = 3) for 
15 min, and with d 250 IU/mL 
or e 2000 IU/mL IFNα-2b or 
IFNα-Le for 48 h (n = 3). Only 
proteins significantly differ-
ently expressed from the control 
samples (p  ≤ 0.05), with a 
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Table 2  Differently expressed proteins in control versus IFNα treated MOLM-13 cells
No. Protein UniProtKB ID DeCyder number p value Fold change Biological process
250 IU/mL IFNα-2b
1 14-3-3 protein epsilon (YWHAE) P62258 2864 0.016 1.45 Cell cycle transition, apoptosis, mem-
brane organization
2 Armadillo repeat-containing protein 6 
(ARMC6)
Q6NXE6 1602 0.017 − 1.32 Unknown
3 Nascent polypeptide-associated com-
plex subunit alpha (NACA)
Q13765 2377 0.02 − 1.44 DNA dependent transcription, transla-
tion
4 Vacuolar protein sorting-associated 
protein 4B (VPS4B)
O75351 1659 0.023 − 1.30 Cell cycle, ATP catabolic process
5 40S ribosomal protein S4, X isoform 
(RPS4X)
P62701 2772 0.025 1.44 Translation, positive regulation of 
proliferation
6 UBX domain-containing protein 1 
(UBXN1)
Q04323 2165 0.026 1.60 Negative regulation of protein ubiqui-
tination
7 Triosephosphate isomerase (TPI1) P60174 2942 0.029 1.40 Glycolysis, metabolic process
8 Ras-related protein Rab-11B 
(RAB11B)
Q15907 3213 0.032 − 1.58 GTPase mediated signal transduction, 
cell cycle
9 26S protease regulatory subunit 7 
(PSMC2)
P35998 1805 0.039 − 1.84 DNA damage response, negative 
regulation of apoptosis, cell cycle 
transition
10 F-actin-capping protein subunit 
alpha-1 (CAPZA1)
P52907 2493 0.047 − 1.42 Actin cytoskeleton organization, blood 
coagulation, immune response
11 40S ribosomal protein SA (RPSA) P08865 2087 0.047 − 1.30 Translation, RNA metabolic process
2000 IU/mL IFNα-2b
1 Nascent polypeptide-associated com-
plex subunit alpha (NACA)
Q13765 2377 0.011 − 1.31 DNA dependent transcription, transla-
tion
2 Alpha-enolase (ENO1) P06733 1789 0.017 − 1.31 Glycolysis, negative regulation of cell 
growth
3 T-complex protein 1 subunit alpha 
(TCP1)
P17987 1355 0.021 − 1.35 Protein folding, tubulin complex 
assembly, cellular protein metabolic 
process
4 Peroxiredoxin-2 (PRDX2) P32119 3214 0.023 − 1.30 Response to oxidative stress, negative 
regulation of apoptosis
5 Adenylate kinase 2 (AK2) P54819 2753 0.047 1.37 ATP metabolic process, oxidative 
phosphorylation
6 40S ribosomal protein SA (RPSA) P08865 2087 0.05 − 1.55 Translation, RNA metabolic process
250 IU/mL IFNα-Le
1 Protein disulfide-isomerase (P4HB) P07237 1663 0.00028 1.46 Protein folding, lipoprotein metabolic 
process, cell redox homeostasis
2 T-complex protein subunit zeta 
(CCT6A)
P40227 1137 0.003 − 1.52 Protein folding, protein transport
3 F-actin-capping protein subunit beta 
(CAPZB)
P47756 2679 0.0063 1.43 Actin cytoskeleton organization, blood 
coagulation
4 L-lactate dehydrogenase B chain 
(LDHB)
P07195 2474 0.0067 − 1.34 Glycolysis, oxidation–reduction 
process
5 F-actin-capping protein subunit beta 
(CAPZB)
P47756 2719 0.009 1.41 Actin cytoskeleton organization, blood 
coagulation
6 U1 small nuclear ribonucleoprotein A 
(SNRPA)
P09012 2589 0.0099 1.30 Gene expression, nuclear mRNA 
splicing
7 Aldose reductase (AKR1B1) P15121 2292 0.011 − 1.31 Response to stress, carbohydrate 
metabolic process, daunorubicin and 
doxorubicin metabolic process
8 UBX domain-containing protein 1 
(UBXN1)
Q04323 2165 0.015 1.89 Negative regulation of protein ubiqui-
tination
9 F-actin-capping protein subunit 
alpha-1 (CAPZA1)
P52907 2493 0.016 − 1.56 Glycolysis, oxidation–reduction 
process
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The samples were subsequently stained with the antibody 
panels (Online Resource Tables 1 and 2) following the Max-
Par phospho-protein staining protocol (Fluidigm), with minor 
adjustments. Briefly, amendments to the protocol include; Fc 
receptors blocking was done using Human IgG  (Octagam®, 
Octapharma, Lachen, Switzerland) for 20 min at RT. To 
block nonspecific antibody binding to eosinophils (Rahman 
et al. 2016), samples were pre-incubated with 100 IU hepa-
rin sodium (Wockhardt, Wrexham, UK) for 20 min, and sub-
sequently stained with antibody cocktails (Online Resource 
Tables 1 and 2) in the presence of 100iU heparin. DNA inter-
calation stain (iridium, Fluidigm) was diluted at 1:1250 in 
4% PFA in Maxpar PBS, and samples were incubated at 4 °C 
overnight. After staining, samples were resuspended in a 1:8 
solution of Maxpar cell acquisition solution (Fluidigm) and 
EQ™ four element calibration beads (Fluidigm).
Acquisition of samples was done using a Helios mass 
cytometer (Fluidigm). After acquisition, the collected data 
was normalized to EQ bead standard (Finck et al. 2013) and 
exported to FCS3 files. Data was subsequently uploaded to 
Cytobank Cellmass software (Cytobank Inc, Santa Clara, CA, 
USA) and evaluated using established methods (Diggins et al. 
2015; Levine et al. 2015). Phenograph was run with the Cyt 
interphase in Matlab (Mathworks, Natick, MA, USA), see 
Online Resource Fig. 1 for gating strategy. The non-parametric 
Kruskal–Wallis H test was used to determine statistical sig-
nificance (p < 0.05) using R software (R Core Team (2017), R 
Foundation for Statistical Computing, Vienna, Austria).
Phospho‑flow cytometry staining and analysis
Treated MOLM-13 cells were washed in 0.9% NaCl, fixated in 
1.6% PFA for 15 min at room temperature (RT), added ice-cold 
methanol and stored at − 80 °C prior to analysis. Samples were 
fluorescently barcoded using Pacific Blue and Pacific Orange 
(Molecular Probe, Eugene, OR, USA), as described previously 
(Krutzik and Nolan 2006). The Student’s unpaired, two-tailed t 
test (GraphPad, GraphPad Software, Inc., La Jolla, CA, USA) 
was used to determine statistical significance (p < 0.05). Pri-
mary antibodies are described in Online Resource Table 3.
Table 2  (continued)
No. Protein UniProtKB ID DeCyder number p value Fold change Biological process
10 Triosephosphate isomerase (TPI1) P60174 2942 0.016 1.56 Glycolysis, metabolic process
11 Isocitrate dehydrogenase (NAD) 
subunit alpha (IDH3A)
P50213 2367 0.021 − 1.46 Carbohydrate metabolic process, oxida-
tion–reduction process
12 Actin, cytoplasmic 2 (ACTG1) P63261 2075 0.022 − 1.60 Immune response, cellular membrane 
organization
13 L-lactate dehydrogenase B chain 
(LDHB)
P07195 2331 0.022 − 1.31 Glycolysis, oxidation–reduction 
process
14 Pyruvate kinase isozymes M1/M2 
(PKM2)
P14618 1380 0.026 − 1.41 Response to hypoxia, programmed cell 
death, ATP biosynthetic process
15 Pyruvate kinase isozymes M1/M2 
(PKM2)
P14618 1381 0.028 − 1.43 Response to hypoxia, programmed cell 
death, ATP biosynthetic process
16 N-alpha-acetyltransferase 10 
(NAA10)
P41227 2695 0.028 − 1.46 Protein amino acid acetylation
17 Annexin A2 (ANXA2) P07355 2977 0.036 − 1.36 Angiogenesis, collagen fibril organiza-
tion
2000 IU/mL IFNα-Le
1 14-3-3 protein epsilon (YWHAE) P62258 2864 0.00047 1.53 Cell cycle transition, apoptosis, mem-
brane organization
2 F-actin-capping protein subunit beta 
(CAPZB)
P47756 2679 0.0012 1.60 Actin cytoskeleton organization, blood 
coagulation
3 Heat shock protein 105 kDa (HSPH1) Q92598 436 0.016 1.34 Unfolded protein response, positive 
regulation of NK cell activation
4 Acidic leucine-rich nuclear phos-
phoprotein 32 family member A 
(ANP32A)
P39687 2739 0.018 1.36 Regulation of DNA dependent gene 
expression, RNA metabolic process
5 Actin, cytoplasmic 2 (ACTG1) P63261 2075 0.029 − 1.36 Immune response, cellular membrane 
organization
Positive fold change indicates higher protein expression in IFNα treated cells compared to control treatment; negative fold change indicates 
lower protein expression by IFNα treatment compared to control treatment. DeCyder number refers to ID assigned by the DeCyder software; p 
value was obtained by Students T test
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Table 3  Differently expressed proteins in MOLM-13 cells treated with IFNα-Le versus IFNα-2b
Positive fold change indicates higher protein expression in IFNα-2b treated cells compared to IFNα-Le treatment; negative fold change indicates 
higher protein expression by IFNα-Le treatment compared to IFNα-2b treatment. DeCyder number refers to ID assigned by the DeCyder soft-
ware; p value was obtained by Students T test
No. Protein UniProtKB ID DeCyder number p value Fold change Biological process
250 IU/mL IFNα-Le versus IFNα-2b
1 L-lactate dehydrogenase B chain (LDHB) P07195 2331 0.00019 1.41 Glycolysis, oxidation–reduction process
2 Aldose reductase (AKR1B1) P15121 2292 0.00079 1.31 Response to stress, carbohydrate metabolic 
process
3 N-alpha-acetyltransferase 10 (NAA10) P41227 2695 0.0039 1.32 Protein amino acid acetylation
4 Pyruvate kinase isozymes M1/M2 (PKM2) P14618 1376 0.03 1.40 Response to hypoxia, programmed cell 
death, ATP biosynthetic process
5 Catalase (CAT) P04040 646 0.038 1.30 Hydrogen peroxide catabolic process, nega-
tive regulation of apoptosis, cell division
6 Pyruvate kinase isozymes M1/M2 (PKM2) P14618 1381 0.04 1.39 Response to hypoxia, programmed cell 
death, ATP biosynthetic process
7 26S protease regulatory subunit 7 
(PSMC2)
P35998 1805 0.05 − 1.76 DNA damage response, negative regulation 
of apoptosis, cell cycle transition
2000 IU/mL IFNα-Le versus IFNα-2b
1 14-3-3 protein epsilon (YWHAE) P62258 2864 0.00014 − 1.47 Cell cycle transition, apoptosis, membrane 
organization
2 28S ribosomal protein 23 (MRPS23) Q9Y3D9 3180 0.00032 − 1.30 Translation
3 40S ribosomal protein S4, X isoform 
(RPS4X)
P62701 2797 0.00093 1.36 Translation, positive regulation of prolifera-
tion
4 Plastin-2 (LCP1) P13796 1244 0.0015 − 1.48 Protein folding, response to stress, cell cycle, 
ATP catabolic process
5 Sorting nexin-5 (SNX5) Q9Y5X3 1628 0.0057 − 1.43 Protein transport, cell communication
6 Acidic leucine-rich nuclear phosphopro-
tein 32 family member A (ANP32A)
P39687 2739 0.0076 − 1.56 Regulation of DNA dependent gene expres-
sion, RNA metabolic process
7 Transgelin-2 (TAGLN2) P37802 3189 0.0077 − 1.43 Actin organization, muscle organ develop-
ment
8 Heat shock protein HSP 90-beta 
(HSP90AB1)
P08238 829 0.0097 − 1.51 Protein folding, response to stress, activation 
of innate immune response, regulation of 
type I IFN mediated signaling pathway
9 Alpha-enolase (ENO1) P06733 1789 0.013 − 1.50 Glycolysis, negative regulation of cell 
growth
10 Protein deglycase DJ-1 (PARK7) Q99497 3207 0.015 − 1.39 Autophagy, negative regulation of cell death, 
response to stress, proteolysis
11 14-3-3 protein epsilon (YWHAE) P62258 2866 0.023 − 1.43 Cell cycle transition, apoptosis, membrane 
organization
12 Spermidine synthase (SRM) P19623 2651 0.034 1.33 Polyamine metabolic process, spermidine 
biosynthetic process
13 Heat shock protein beta-1 (HSPB1) P04792 3078 0.034 − 1.67 Angiogenesis, anti-apoptosis, response to 
stress, response to unfolded protein
14 WD repeat-containing protein 1 (WDR1) O75083 1104 0.035 − 1.31 Platelet degranulation and activation
15 78 kDa glucose-regulated protein (HSPA5) P11021 3366 0.04 − 1.42 Platelet degranulation and activation, anti-
apoptosis, unfolded protein response, 
negative regulation of TGFβ receptor 
signaling pathway, positive regulation of 
protein ubiquitination
16 Heat shock cognate 71 kDa protein 
(HSPA8)
P11142 1158 0.041 − 1.41 Protein folding, response to stress, response 
to unfolded protein, cell cycle, ATP cata-
bolic process
17 T-complex protein 1 subunit alpha (TCP1) P17987 1355 0.043 − 1.44 Protein folding, tubulin complex assembly, 
cellular protein metabolic process
18 Annexin A5 (ANXA5) P08758 2652 0.045 − 1.31 Anti-apoptosis, signal transduction
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Viability and cell death assays
Viability was determined using Annexin-V Alexa Fluor 488 
(Life Technologies Ltd, Paisley, UK) and Propidium Iodide 
(PI) (Sigma-Aldrich), and cell death was analyzed by Hoechst 
33342 DNA staining (Calbiochem, Merck KGaA, Darmstadt, 
Germany) as described in the Online Resources.
IMAC phosphoprotein purification, two‑dimensional 
differential gel electrophoresis, gel analysis 
and protein identification by mass spectrometry 
(IMAC/2D DIGE/MS)
Phosphoproteins were enriched using the PhosphoProtein 
Purification Kit (Qiagen, Hilden, Germany) as recom-
mended by the manufacturer. In short, 1 × 107 cells were 
lysed after IFNα treatment (48 h) as previously described 
(Forthun et al. 2012). Subsequently, phosphoprotein sam-
ples were covalently labeled with fluorescent CyDyes (GE 
Healthcare, Chicago, Illinois, US) in a minimal labeling 
reaction (400 pmol dye:50 µg protein) and isoelectrically 
focused on pH 3–11 DryStrip Immobiline gel strips (GE 
Healthcare) prior to second dimension gel electrophoresis 
and mass spectrometry identification as described in the 
Online Resources.
Animals
Fifteen 240–320 g male Brown Norwegian rats (BN/mcwi) 
(Charles River Laboratories, Wilmington, MA, USA) and 
40 20–25 g female NOD/Scid IL2 γ−/− (NSG) mice (the 
Vivarium, University of Bergen, Norway, originally a gener-
ous gift from Prof. Leonard D. Shultz, Jackson Laboratories, 
Bar Harbour, Maine, USA) were injected intravenously in 
the lateral tail vein with 10 million BNML cells or 5 million 
MOLM-13Luc+ cells, respectively. Animals were dosed with 
VPA intraperitoneally (BNML; 400 mg/kg, n = 4, MOLM-
13Luc+; 350  mg/kg, n = 7), IFNα-Le by subcutaneous 
Fig. 2  IFNα induce cell death 
in human MOLM-13 AML 
cells. Viability was investigated 
by Annexin-V/PI after 48 h 
treatment with recombinant 
IFNα-2b, IFNα-Le and/or 
1 mM VPA (n = 3). Cell death 
percentages were normalized to 
control cells. a MOLM-13 cells 
showed statistically significant 
increased percent cell death 
when treated with IFNα or VPA 
(Student’s unpaired, two tailed 
t test). Combining 1 mM VPA 
with 2000 IU/ml IFNα resulted 
in synergism compared to single 
treatments for both b IFNα-2b 
(two-way ANOVA, *p =0.009) 
and c IFNα-Le (two-way 
ANOVA, **p = 0.001), as com-
pared to the theoretical additive 
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injections (BNML; 0.8x106 IU/kg—human equivalent dose 
0.13 × 106 IU/kg, n = 4, MOLM-13Luc+; 1 × 106 IU/kg—
human equivalent dose 0.08 × 106 IU/kg, n = 7), or a combi-
nation of VPA and IFNα-Le (BNML; n = 4, MOLM-13Luc+; 
n = 7). Control groups (BNML; n = 3, MOLM-13Luc+; n = 7) 
received subcutaneous injections of 0.9% NaCl (Fresenius 
Kabi AG, Bad Homburg, Germany). Calculation of IFNα-Le 
doses was based on relevant therapeutic doses and is 
described in the Online Resources. Treatment was initiated 
day 10 (BNML) or day 7 (MOLM-13Luc+), with VPA 5 days 
successively per week, and IFNα-Le three times a week (day 
1, 3 and 5) for a total of 4 weeks. MOLM-13Luc+ mice were 
imaged by bioluminescent optical imaging once a week as 
described in the Online Resources. Animals were sacri-
ficed at humane endpoint, defined as loss of body weight 
(mice 10%, rats 15%), ataxia, paralysis of hind or fore limbs, 
lethargy or dehydration. Survival ratios were investigated 
by Log-rank (Mantel-Cox) Test on Kaplan–Meier curves 
(GraphPad). All applicable international, national and insti-
tutional guidelines for the care and use of animals were fol-
lowed for all animal studies. The animal experiments were 
reviewed and approved by The Norwegian Animal Research 
Authority under study permit number 2009 1955 and 2015 
7229 and conducted according to The European Conven-
tion for the Protection of Vertebrates Used for Scientific 
Purposes.
Results
Phosphoproteome analysis of IFNα‑Le and IFNα‑2b
We investigated the difference in phosphoprotein regulation 
between the two IFNα compounds IFNα-Le and IFNα-2b by 
immobilized affinity chromatography (IMAC) and 2D DIGE 
in the human AML cell line MOLM-13 (48 h treatment). 
2D DIGE showed a total of 47 proteins with higher than 1.3 
fold change and a significance level of p ≤0.05 between the 
compounds (Fig. 1a, Tables 2 and 3). Only nascent poly-
peptide-associated complex subunit alpha (NACA) and 40S 
ribosomal protein SA (RPSA) were modulated at both 250 
and 2000 IU/mL IFNα-2b. For IFNα-Le only F-actin-cap-
ping protein subunit beta (CAPZB) and actin cytoplasmic 2 
(ACTG1) were modulated at 250 and 2000 IU/mL (Table 2). 
The majority of the IFNα regulated proteins demonstrated 
a down-regulation after low dose treatment. IFNα-2b at 
Fig. 3  Phospho-signaling 
induced by VPA and IFNα-Le 
in MOLM-13 cells. MOLM-
13 cells (n = 3) were treated 
with VPA (1 mM) and/or 
IFNα-Le (2000 IU/mL) and 
analyzed by flow cytom-
etry. a Significantly different 
expressed proteins after 15 min 
(p ≤0.05, fold change ≥ 1.3). 
b Significantly different 
expressed proteins after 48 h 
(p ≤0.05, fold change ≥ 1.3). 
Scale describes fold change 
 log2 compared to untreated 
control cells (Students unpaired 
two-tailed t test, *p <0.05, 
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250 IU/mL induced down-regulation of proteins involved 
in cell cycle [Ras-related protein Rab-11B (RAB11B)], 
DNA damage response [26S protease regulatory subunit 7 
(PSMC2)] and immune response [F-actin-capping protein 
subunit alpha-1 (CAPZA1)]. At 2000 IU/mL, up-regulation 
of adenylate kinase 2 (AK2), a protein necessary for the 
hematopoiesis (Pannicke et al. 2009) and unfolded protein 
response (UPR) (Burkart et al. 2011), was found. This was 
accompanied by down-regulation of proteins involved in 
transcription and translation [NACA and 40S ribosomal pro-
tein SA (RPSA)], as well as oxidative stress response protein 
peroxiredoxin-2 (PRDX2). IFNα-Le regulated the expres-
sion of proteins involved in protein folding, stress response 
and programmed cell death even at 250 IU/mL (T-complex 
protein subunit zeta (CCT6A), aldose reductase (AKR1B1) 
and pyruvate kinase isozymes M1/M2 (PKM2), respec-
tively). Additionally, proteins involved in energy production 
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MOLM-13Luc+ NOD/Scid IL2γ-/- mouse model 
Fig. 4  Survival of MOLM-13Luc+ NSG mice and BNML rats treated 
with valproic acid and IFNα-Le. a  MOLM13Luc+ NSG mice (n = 2) 
were imaged weekly after inoculation with 5 million  MOLM13Luc+ 
cells. Representative images shows leukemic cell infiltrates day 21 
for control and IFNα-Le-treated mice. b Total photon counts (ven-
tral) shows lower tumor burden in VPA-treated mice (n = 2) compared 
to other treatments. c MOLM-13Luc+ NSG mice show significantly 
increased survival by VPA mono- and combination treatment com-
pared to IFNα-Le-treated mice (n = 7). d BNML rats showed signifi-
cantly increased survival by VPA treatment (n = 4). Treatment period 
is indicated in grey. e Blood samples and spleens were harvested at 
humane endpoint (paired t test *p = 0.04, **p = 0.01). Samples from 
IFNα-Le mono-therapy could not be obtained
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dehydrogenase (NAD) subunit alpha (IDH3A)] were down-
regulated. At 2000 IU/mL only cytoskeletal protein ACTG1 
was down-regulated, whilst adapter protein 14-3-3 protein 
epsilon (YWHAE), actin regulator CAPZB, UPR-response 
Heat shock protein 105 kDa (HSPH1) and gene expression 
regulator acidic leucine-rich nuclear phosphoprotein 32 fam-
ily member A (ANP32A) were up-regulated.
The expression differences induced by IFNα-2b and 
IFNα-Le demonstrated no overlap between proteins regu-
lated at low and high dose (Table 3). At 250 IU/mL, 6 of 
7 proteins had lower expression after IFNα-Le treatment, 
whilst only PSMC2 was regulated by IFNα-2b (Online 
Resource Table 4). This effect was reversed at 2000 IU/
mL where 16 of 18 proteins showed higher expression after 
IFNα-Le treatment compared to IFNα-2b, exemplified by 
up-regulation by IFNα-Le for YWHAE and ANP32A, or 
down-regulation by IFNα-2b for alpha-enolase (ENO1), 
heat shock protein beta-1 (HSPB1) and T-complex protein 
1 subunit alpha (TCP1).
Altered intracellular signaling by IFNα‑Le 
and IFNα‑2b
To investigate proteins known to be regulated by IFNα, 
we explored early (15 min) and late (48 h) effects on phos-
phorylation of signaling proteins involved in cell cycle 
progression and cell death pathways, as well as IFNα-
regulated phosphoproteins in the AML cell line MOLM-13 
by phospho-flow cytometry (antibody overview in Online 
Resource Table 3). Only proteins with a fold change ≥ 1.3 
(p ≤ 0.05) compared to untreated control cells were regarded 
regulated by the drug treatment. After 15 min exposure, 
both 250 and 2000  IU/mL IFNα induced phosphoryla-
tion of STAT1 (pY701), STAT3 (pY705, pS727), STAT5 
(pY694) and STAT6 (pY641) (Fig. 1b, c, Online Resource 
Fig. 2A). In addition, the high dose induced phosphoryla-
tion of CREB (pS133), as well as S6 ribosomal protein (S6) 
(pS235/pS236) and the known IFNα effector MAP kinase 
p38 (pT180/pY182) (Fig. 1c). All proteins were similarly 
regulated by the two drugs except for STAT6, which showed 
significantly higher phosphorylation (p = 0.002) by IFNα-2b 
compared to IFNα-Le (Fig. 1b).
After 48 h, only STAT1, STAT5 and STAT6 showed 
increased phosphorylation compared to control cells 
(Fig. 1d, e, Online Resource Fig. 2B). Both IFNα-2b and 
IFNα-Le resulted in significantly increased phosphorylation 
of STAT3, p38, ERK1/2, NFκB and p53 (pS15) at the high 
dose treatments compared to control cells, however, below 
threshold limits (Online Resource Fig. 2). No differences in 
protein phosphorylation could be detected between IFNα-2b 
and IFNα-Le at 48 h.
IFNα‑Le induces cell death more efficiently 
than recombinant IFNα‑2b
Since IFNα-2b and IFNα-Le differed in the regulation of 
both known and previously unknown IFNα-regulated pro-
teins, we investigated the difference in cell death induction 
by the two drugs. VPA and IFNα have been reported to act 
synergistically in several cancer models (Jones et al. 2009; 
Iwahashi et al. 2011; Hudak et al. 2012), and we, therefore, 
combined the two drugs with the aim of increasing the mod-
est apoptotic effects of IFNα. MOLM-13 cells were treated 
for 48 h and analyzed by Hoechst (Online Resource Fig. 3) 
and Annexin-V/PI staining (Fig. 2). We found that both 
IFNα-2b and IFNα-Le induced a low but significant increase 
in apoptosis compared to the control. Whilst increasing the 
concentration of IFNα-2b from 250 to 2000 IU/mL did not 
result in significantly increased levels of cell death, 2000 IU/
mL IFNα-Le caused elevated levels of cell death (p =0.04) 
(Fig. 2a). Combining 2000 IU/mL IFNα-2b with 1 mM VPA 
increased the levels of cell death synergistically (46.0%, 
p =0.01) (Fig. 2b), whilst the combination of 2000 IU/ml 
IFNα-Le with 1 mM VPA was more efficient at inducing 
cell death (55.1%, p = 0.009) (Fig. 2c). For the rat IPC-81 
cell line, VPA significantly induced cell death compared to 
the control (Online Resource Fig. 4A). However, no effect 
was seen on apoptosis by either IFNα drugs, even though 
2000 IU/mL IFNα-Le induced STAT1 (pY701) phospho-
rylation (Online Resource Fig. 4B).
Phosphoprotein signaling by the valproic acid/
IFNα‑Le combination
To unravel the reason for the synergistic effect seen by 
IFNα-Le and VPA in MOLM-13 cells, we performed phos-
pho-flow exploring the same proteins as described above 
for IFNα mono-therapy. Altered phosphorylation that could 
account for the observed synergistic effect was not found for 
any of the analyzed proteins. Treatment with 1 mM VPA for 
15 min resulted in increased acetylation of p53 (acK382), 
whereas no significant change was induced by IFNα-Le 
(Fig. 3a, Online Resource Fig. 2C). VPA also induced a 
slight increase in phospho-ERK1/2 (pT202/pT204) and 
phospho-p38 (pT180/pY182), similar to the response seen 
after IFNα-Le treatment, indicating p38 and ERK1/2 as com-
mon downstream targets for VPA and IFNα-Le. After 48 h, 
acetylation of p53 remained to be the main cellular response 
to VPA treatment, whereas both drugs induced phosphoryla-
tion of ERK1/2, p38, p53 (pS15) and Akt (pT308) (Fig. 3b, 
Online Resource Fig. 2D). The increase in S15 phosphoryla-
tion of p53 induced by IFNα-Le indicates that the previously 
reported induction of p53 by IFNα (Takaoka et al. 2003) 
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Fig. 5  Signaling pathways altered by IFNα-2b and VPA in healthy 
PBMCs. PBMCs from healthy donors treated with IFNα-2b and VPA 
and combination IFNα-2b/VPA for 48  h ex  vivo were evaluated by 
CyTOF to investigate alterations in intracellular signaling pathways 
in defined cell subsets. Data are presented as arcsinh ratio relative 
to control. Statistics are based on treated cells compared to control. 
Kruskal–Wallis H test *p ≤ 0.05, **p ≤ 0.01
◂
may be caused by p53 S15 phosphorylation and not acetyla-
tion. A STRING analysis of proteins found to be regulated 
by IFNα in this study and proteins regulated by VPA in our 
previous study (Forthun et al. 2012) showed that several pro-
teins were connected, and also showed that proteins found 
by 2D DIGE interacted with proteins known to be regulated 
by IFNα (YWHAE and MAPK3(ERK1)/MAPK1(ERK2)/
AKT1) (Online Resource Fig. 5).
Interferon‑α gives no survival benefit 
in MOLM‑13Luc+ NOD/Scid IL2 γ−/− xenograft mouse
To further explore the observed in vitro synergistic effects 
of VPA and IFNα, we used the MOLM-13Luc+ NOD/Scid 
IL2 γ−/− xenograft mouse model. Tumor load evaluation by 
bioluminescent imaging showed that control mice and mice 
treated with IFNα-Le (1 × 106 IU/kg) developed tumors in 
femurs and lymph nodes after 21 days, whilst animals treated 
with VPA showed detectable tumors 7 days later (Fig. 4a). 
At day 32, mice treated with VPA (350 mg/kg) showed the 
lowest tumor burden. Control mice had higher tumor burden 
compared to IFNα-Le-treated mice (Fig. 4b), but IFNα-Le-
treated mice developed hind limb paralysis earlier than other 
treatment groups. They did, however, not have significantly 
reduced survival compared to control mice (p = 0.118). 
VPA-treated and VPA/IFNα-Le combination treated mice 
had significantly longer survival compared to mice treated 
with IFNα-Le as monotherapy (p = 0.0008 and 0.0294, 
respectively) (Fig. 4c). Necropsy revealed tumor infiltration 
in lymph nodes and ovaries but no signs of splenomegaly.
VPA treatment significantly increases survival 
in immune‑competent BN myeloid leukemia rats
The anti-leukemic effects of IFN-α are attributed both to a 
direct action on AML cells and an indirect effect through 
immune activation (Anguille et al. 2011). As the MOLM-
13Luc+ NOD/Scid IL2 γ−/− model is lacking a functional 
immune system, we further investigated whether the 
synergistic apoptotic effect observed in MOLM-13 cells 
could be reproduced in vivo using the immune-compe-
tent BNML rat model. Control rats and rats treated with 
IFNα-Le (0.8 × 106 IU/kg) mono-therapy rapidly presented 
with hunched posture and paralysis of hind limbs due to 
the accumulation of leukemic blasts in the bone marrow, 
and showed median survival of 21 and 22 days, respec-
tively (Fig. 4d). Animals treated with VPA (400 mg/kg), 
both as mono-therapy and in combination with IFNα-Le, 
showed no signs of disease during the treatment period 
and had consistently lower spleen size, white blood cell 
counts and higher number of platelets (Fig. 4e) compared 
to control animals. Rats treated with VPA alone and in 
combination with IFNα-Le also showed significantly 
longer survival compared to control rats (p = 0.01) and 
compared to IFNα-Le monotherapy (p = 0.007). Combin-
ing IFNα-Le and VPA (median survival 53 days) gave a 
slight but non-significant prolonged survival (p = 0.07) 
compared to VPA alone (median survival 50  days), 
whereas no survival benefit was seen for IFNα-Le mono-
therapy. The dose of IFNα-Le used in both the rat and 
mouse model was slightly higher than the dose chosen for 
a cutaneous melanoma study (Stadler et al. 2006), but is 
in line with the current practice for IFNα-2b treatment of 
chronic myeloid leukemia and chronic hepatitis B (Online 
Resources).
Single cell mass cytometry analysis of PBMCs 
from AML patients and healthy donors
To assess whether the signaling and anti-apoptotic effects 
observed by IFNα treatment in MOLM-13 was a cell line-
specific effect, we treated 12 AML patient and five healthy 
donor PBMC samples using the same therapy combination 
(48 h). Using cleaved caspase-3 (cCaspase 3) as a surro-
gate for apoptosis detection, we found that the two drugs 
affected healthy donor (Fig. 5) and AML patient PBMCs 
(Fig. 6) differently. IFNα-2b was the only drug to signifi-
cantly increase cleaved caspase-3 in healthy donor cells 
(monocytes; p = 0.007, natural killer (NK) cells; p = 0.007, 
NK T-cells; p = 0.007). For AML patients, the blast popu-
lation had significantly increased cleaved caspase-3 by 
VPA (VPA; p = 0.003, VPA/IFNα-2b; p = 0.0002). In 
 CD4+CD7− T cells from AML patients VPA decreased 
(p = 0.030) and IFNα-2b increased cleaved caspase-3 
levels (p = 0.017), whereas IFNα-2b gave increased cas-
pase-3 levels in double-negative (DN) T cells (IFNα-2b; 
p = 0.003, VPA/IFNα-2b; p = 0.038). No synergistic effects 
of apoptosis induction were observed by combination ther-
apy in healthy or AML samples.
VPA was found to significantly induce acetylation of p53 
(K382) and IFNα-2b to significantly induce phosphorylation 
of STAT1 (Y701) and STAT3 (Y705) both in healthy donor 
and AML PBMCs (Figs. 5 and 6), validating the finding 
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Fig. 6  Signaling pathways altered by IFNα-2b and VPA in AML 
patient-derived PBMCs. PBMCs from AML patients treated with 
IFNα-2b and VPA and combination IFNα-2b/VPA for 48 h ex vivo 
were evaluated by CyTOF to investigate alterations in intracellular 
signaling pathways in defined cell subsets. Data are presented as arc-
sinh ratio relative to control. Statistics is based on treated cells com-
pared to control. Kruskal–Wallis H test *p ≤ 0.05, **p ≤ 0.01
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made by flow cytometry in the MOLM-13 cell line (Fig. 3). 
NPM1 wild type patients had higher levels of pSTAT1 after 
IFNα-2b treatment compared to mutated patients (DN T 
cells; p = 0.049) (Online Resource Fig. 6).
Investigating the immune-modulating effects of both 
VPA and IFNα-2b (see Online Resource Table 2 for anti-
body panel), we observed that IFNα-2b treatment of healthy 
PBMCs (Fig. 7) up-regulated CD141 on plasmacytoid den-
dritic cells (pDCs; p = 0.021), and up-regulated PD-L1 
 (CD4+ T cells; p = 0.025,  CD4+CD7− T cells; p = 0.007, DN 
T cells; p = 0.011, monocytes; p = 0.007, B cells; p = 0.007 
and NK cells; p = 0.007), CD45RO (monocytes; p = 0.007), 
CD86 (monocytes; p = 0.007, B cells; p = 0.007) and TIM3 
(NK cells; p = 0.007). For AML patient PBMCs (Fig. 8), 
no significant change in levels of CD141, CD45RO, CD86 
or TIM3 was found by IFNα-2b treatment. CD45RA was, 
however, slightly increased in blasts (p = 0.034) and mono-
cytes (p = 0.021). PD1  (CD4+CD7− T cells; p = 0.017) 
and PD-L1 (blasts; p = 0.05,  CD8+ T cells; p = 0.006, 
 CD4+CD7− T cells; p = 0.017, DN T cells; p = 0.038, mono-
cytes; p = 0.021) were also increased by IFNα-2b treatment. 
Comparing healthy donor and AML PBMCs after IFNα-2b 
treatment showed that healthy donors had monocytes with 
stronger induction of PD-L1 (p = 0.014), CD86 (p = 0.05) 
and CD45RO (p = 0.049) in addition to pDCs with higher 
levels of CD141 (p = 0.023), whereas AML patients had 
 CD4+CD7− T cells with increased levels of PD1 (p = 0.022). 
Subdividing patients according to karyotype (Online 
Resource Fig. 7) showed that patients with normal karyo-
type had higher levels of PD-L1 compared to patients with 
complex karyotype (pDCs); p = 0.032) after IFNα-2b treat-
ment. B cells in NPM1 mutated patients (Online Resource 
Fig. 6) had higher levels of CD45RA compared to wild type 
patients (p = 0.032). No significant changes were found 
by IFNα-2b monotherapy between FLT3 internal tandem 
duplication (ITD) mutated and wild type patients (Online 
Resource Fig. 9).
Discussion
The phosphoproteome analysis identified the acetyl trans-
ferase protein NAA10 as selectively down regulated by 
IFNα-Le and a potential overlapping signal pathway with the 
histone deacetylase inhibitor VPA. Knock-down of NAA10 
has been found to increase apoptosis and increase the sen-
sitivity to daunorubicin in vitro (Arnesen et al. 2006). Fur-
thermore, mutations in the auto-acetylation site of NAA10 
inhibit lung tumor xenograft growth in vivo (Seo et al. 
2010). YWHAE and PKM2 expression were also induced 
by IFNα-Le, and knockdown of these proteins has been 
shown to result in increased invasion, migration and pro-
liferation in gastric cancer cell lines (Leal et al. 2016), and 
inhibition of drug-induced differentiation in leukemic K562 
cells (Chaman et al. 2015). Additionally, mRNA expres-
sion of YWHAE, ARMC6, RAB11B, P4HB, SNRPA and 
ANP32A is down-regulated and CAPZB up-regulated by 
VPA in AML cell lines (Rucker et al. 2016), further sup-
porting the existence of overlapping signaling pathways for 
IFNα and VPA. STRING pathway analysis of proteins regu-
lated by IFNα and VPA (Forthun et al. 2012) also showed 
several interactions (Online Resource Fig. 5) determined 
experimentally.
Previous case reports indicate that secondary AML 
transformed from essential thrombocytosis or myelofibro-
sis particularly benefit from IFNα therapy (Berneman et al. 
2010; Dagorne et al. 2013). In the light of the biological and 
molecular heterogeneity in AML (Dohner et al. 2017), this 
may suggest that a particular AML subset is sensitive for 
IFNα. This was, however, not the case for our patient cohort, 
although the number of individuals was limited. Importantly, 
immediate and rapid progressing disease has been described 
in acute lymphoblastic leukemia patients treated with lower 
doses of IFNα (Ochs et al. 1986) and in vitro testing of AML 
cells has indicated that approximately a third of the patient 
samples responded with increased clonogenicity when 
treated with lower doses IFNα (Ludwig et al. 1983). Our 
study showed increased in vitro activation of UPR by IFNα-
induced phosphorylation of AK2 and HSPH1 in MOLM-
13 cells. Increased UPR has been shown to promote faster 
tumor growth and resistance to common anticancer drugs in 
xenograft mouse models (Bi et al. 2005; Spiotto et al. 2010). 
Therefore, moderate or low doses IFNα should be used with 
care in AML until we know predictive markers for therapy 
response, like tumor burden and molecularly defined IFNα-
sensitive subtypes of AML.
The anti-tumor effect of IFNα in combination with VPA 
has been suggested experimentally in other cancers (Stadler 
et al. 2006; Iwahashi et al. 2011; Hudak et al. 2012). We 
observed that IFNα was synergistic in combination with 
VPA in MOLM-13 cells in vitro. A similar in vitro and 
in vivo synergism has been demonstrated combining VPA 
with the small molecule MDM2 inhibitor nutlin-3 in the 
MOLM-13Luc+ xenograft model (McCormack et al. 2012). 
However, IFNα-Le treatment of the MOLM-13Luc+ xeno-
graft model indicated no survival benefit, and the same was 
found in the immune competent BNML model. Previous 
studies treating the aggressive BNML model with inter-
feron-inducing BCG demonstrated a similar lack of survival 
benefit in the monotherapy arm (Hagenbeek and Martens 
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Fig. 7  Immune activation markers altered by IFNα-2b and VPA in 
healthy PBMCs. PBMCs from healthy donors treated with IFNα-2b 
and VPA and combination IFNα-2b/VPA for 48 h ex vivo were evalu-
ated by CyTOF to investigate alterations in immune activation mark-
ers in defined cell subsets. Data are presented as arcsinh ratio relative 
to control. Statistics are based on treated cells compared to control. 
Kruskal–Wallis H test *p ≤ 0.05, **p ≤ 0.01
◂
1983). Furthermore, low tumor burden is a prerequisite for 
IFNα anti-tumor response (Eggermont et al. 2012), and we 
cannot exclude that the mouse and rat models used in this 
study may have exceeded the tumor burden accessible for 
beneficial IFNα therapy.
Whereas the lack of anti-leukemic effect of IFNα in the 
mouse model used in our study could also be due to the 
absence of important immune cells needed for an effective 
DC effect against AML cells (Ito et al. 2002), the BNML 
rat model has an intact immune system. The lack of in vivo 
potency of the VPA and IFNα-Le combination in this model 
could be a result of reduced activity of human IFNα-Le in 
rats. However, we did find 2000 IU/mL IFNα-Le to increase 
pSTAT1 (Y701) in BNML derived IPC-81 cells (Online 
Resource Fig. 4), suggesting that human IFNα could be reac-
tive also in BNML rats. Furthermore, activation of rat IFNα 
receptors by human IFNα is supported by reports of reduced 
rat endometriosis by human IFNα (Altintas et al. 2008) and 
in vivo interferon-induced metallothionein (Guevara-Ortiz 
et al. 2005).
It is well established that IFNα activates DCs, T cells 
and NK cells, and thus contributes to the generation of a 
potent anti-leukemic immune response (Zhang et al. 2005; 
Watanabe et al. 2006; Korthals et al. 2007; Willemen et al. 
2015). Investigating immune regulators in healthy and AML 
patient-derived PBMCs revealed that all cellular subsets 
apart from  CD8+ and DN T cells responded by one or more 
markers after IFNα-2b treatment in healthy donor PBMCs. 
For AML-derived PBMCs, however, no response was seen 
in pDCs, NK or NK T cells. We also observed that PBMCs 
from AML patients had different immune-associated 
responses to IFNα-2b compared to healthy donor PBMCs 
(Online Resource Fig. 8). Particularly, lack of activation 
of the differentiation markers CD141, CD45RO and CD86 
in AML patient monocytes and pDCs could indicate that 
patients with AML have an inaccessible immune system 
where cell subsets stay unresponsive to activating stimuli. 
The absence of pSTAT1 (Y701) induction in AML-derived 
pDCs, and not healthy pDCs, further supports the inabil-
ity of these cells to respond to IFNα. The up-regulation of 
CD141 in response to IFNα treatment in healthy pDCs was 
importantly not observed in AML-derived DCs.  CD141+ 
DCs are known to induce differentiation of IL-4- and IL-
13-producing  CD4+ T cells, thereby guiding the adaptive 
immune response (Yu et al. 2014). Thus, the lack of DC acti-
vation in AML samples could explain the lack of response 
to IFNα monotherapy in AML patients. Increased CD86 
promotes myeloid differentiation and suppresses cell prolif-
eration (Fang et al. 2017). AML patients positive for CD86 
have been suggested to be candidates for immunotherapy 
(Re et al. 2002), however, this marker was not activated in 
AML patients. Neither was CD45RO, whose presentation on 
lymphocytes in adult T cell leukemia patients is correlated 
with improved prognosis (Suzuki et al. 1998). Thus, our 
overall results could indicate that there is a combined loss 
of the differentiation potential and lack of immune activa-
tion in the investigated AML patients, suggesting that these 
patients would not benefit from IFNα-monotherapy.
Conclusion
IFNα-2b and IFNα-Le have different effects on the regu-
lation of phospho-protein expression as discovered by 2D 
DIGE proteomic analysis and phospho-flow, and IFNα 
combined with VPA induced cell death synergism in vitro. 
The absence of monocyte and pDC activation by IFNα 
ex vivo could explain the lack of an in vivo anti-leukemic 
effect, and the therapeutic effect of IFNα may potentially be 
enhanced by removing this inherent block of activation in 
healthy immune subsets in AML patients. This needs to be 
addressed in future studies that take into consideration the 
complex tumor-host interactions in AML.





























































































Fig. 8  Immune activation markers altered by IFNα-2b and VPA 
in AML patient-derived PBMCs. PBMCs from AML patients 
treated with IFNα-2b and VPA and combination IFNα-2b/VPA for 
48 h ex vivo were evaluated by CyTOF to investigate alterations in 
immune activation markers in defined cell subsets. Data are presented 
as arcsinh ratio relative to control. Statistics are based on treated cells 
compared to control. Kruskal–Wallis H test *p ≤ 0.05, **p ≤ 0.01
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